Clinical information
Diagnostic Utility:
This is the simultaneous qualitative detection of p24 antigen and antibodies against human immunodeficiency virus type I/II (HIV-1 and HIV-2), and its determination is useful in:
- Detection of recent HIV infection.
- Transfusion of blood products, transplantation of progenitor cells, umbilical cord blood, tissues, and solid organs.
Method:
Chemiluminescent microparticle immunoassay (CMIA).
Reference Values
Possible results are: Reactive and Non-Reactive.
Diagnostic Algorithm:
Not applicable.
Response Time:
Maximum 2 working days.
Specimen information
Sample: Serum and/or plasma
Tube: 1-5 mL aliquots, plasma tubes with EDTA, citrate or heparin as anticoagulants and/or serum tubes with or without gel separator.
Minimum essential volume: 1 ml
Stability:
- At room temperature: ≤ 3 days
- In refrigeration: ≤ 14 days
- Sample frozen at or below -20ºC: 10 years
Transport instructions: Preferably at a temperature of 2ºC and 8ºC (with ice packs), not exceeding 14 days, or at a temperature at or below -20ºC (with dry ice).
Reason for rejection: Highly hemolyzed sample.
Administrative information
BST Code: 2111
Test Description: HIV-1/HIV-2, IgG/antigen P24. Screening.
Synonyms: HIV Ag/Ab Combo.
Section: Transfusion Safety Laboratory
BST Rate: Check the updated rates by clicking here.
Profiles:
N/A
References
- Inserts kits de HIV Ag/Ac Combo Architect, Abbott.
Quality
BST holds ISO 9001, ISO 14001, and OSHAS 18001 quality certifications, as well as the European Excellence 500+ seal. BST is accredited by CAT, JACIE-FACT, FACT-NETCORD, and EFI, and complies with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) guidelines.